Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar continuous intravenous infusion combined with immunotherapy for advanced solid tumors
ChiCTR2300078666Phase 2Recruiting
- Sponsor
- Beijing Chaoyang Sanhuan Cancer Hospital
- Start
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of endostar in Nonhematologic neoplasms, sponsored by Beijing Chaoyang Sanhuan Cancer Hospital. Primary endpoints: Objective response rate, Progression-free survival and 1 more. Started Dec 2023; status: recruiting.
02
Drugs
endostar
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2300078666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078666.